

From: Stephen Harland-Smith
Sent: Tuesday, 12 May 2020 10:35 AM
To: Dwyer, Ellie
Cc: Susan Harland-Smith; Deb Varcoe
Subject: RE: AA1000479 - MTAA interim authorisation - Request for information [SEC=OFFICIAL] [ACCC-ACCCANDAER.FID2539479]

Dear Mrs. Dwyer,

I refer to your email and correspondence dated 11th May, 2020.

This is to advise that ESL Biosciences Australia P/L has not had to enter into any conduct related to the TPA exemption as it has not yet needed to exercise it and that if such a situation arises, I will inform the ACCC.

Yours faithfully,

Stephen Harland-Smith



STEPHEN HARLAND-SMITH
 DIRECTOR



ESL Biosciences Australia (2012) Pty Ltd

Suite 3, 2-4 Giffnock Ave, Macquarie Park, NSW

Telephone +61 2 988 73700



DISCLAIMER: This message (and any attachments) may contain confidential or privileged information. Unless it is part of a contractual obligation, the information contained in this message has been sent by the signatory on their personal initiative and does not bind ESL Biosciences in any way. It is intended only for the recipient(s) to which it was addressed. If you received this in error, please notify the sender by replying and then deleting it from your system. Any review, retransmission, retention, reproduction, or distribution of this message is prohibited and may be unlawful. The integrity and security of this message cannot be guaranteed and it may be subject to data corruption, interception and unauthorized amendment, for which we accept no liability.

EUROIMMUN AG
Complete Test Package for SARS-CoV-2

EURORealTime SARS-CoV-2 RT-PCR

- PCR test for specific detection of SARS-CoV-2
- All required components are included in the kit
- Quick and simple detection by means of reverse transcription and real-time PCR in one step
- Targeting 2 sequences - ORF1ab and N gene
- Only one reaction per sample

Anti-SARS-CoV-2 ELISA IgA and IgG

- Ideal complementary tests to confirm RT-PCR results
- Important for investigation of suspected cases or negative RT-PCR results

	Anti-SARS-CoV-2 ELISA IgA	Anti-SARS-CoV-2 ELISA IgG
Sensitivity		
>10-20 days after symptom onset	100%	87.5%
≥ 21 days after symptom onset	100%	100%
Specificity		
	90.5%	99.3%

[CLICK TO LEARN MORE](#)